الفهرس 
BIOLOGY
HOST IMMUNE RESPONSE TO SARCOPTES SCABIEIOnly 14 pages are availabe for public view
 |  | from | 263 |  |  |
| | | from | 263 | | |
Abstract
In 2020, scabies was included in the WHO roadmap for neglected tropical diseases. While there are no published data about the global incidence rates of crusted scabies (CS), scabies is known to affect 200-300 million people annually worldwide (Leung et al., 2020). All ages could be affected by scabies. However, children and the elderly in poor areas are more susceptible for scabies and its complications (Feldmeier et al., 2009). Diffusion of mite antigens into the dermis could trigger cellular and humoral immune responses, leading to disturbance of the balance between Th1 and Th2 immune responses (Arlian and Morgan, 2017). Heavy infestation could lead to serious physical deterioration and eventually death of the affected host. Till now, it is not entirely clear the mechanisms by which this disease could affect the general condition of the host (De et al., 2020). For a better understanding of the host–parasite interactions in CS, several parameters were used in this work to evaluate local and systemic changes in both untreated and treated experimental animals, with special emphasis on studying histopathological changes, serum biochemical parameters, oxidant/antioxidant balance, and immune parameters. Understanding changes in these parameters could allow establishment of complementary indicators during diagnosis and treatment of scabies, especially in resource-poor countries, to decrease the incidence of erroneous diagnosis and treatment failure (Nwufoh et al., 2019). Till now, ivermectin (IVM) is the only available oral drug used in scabies treatment in humans. However, multiple doses are required for treating CS (Bernigaud et al., 2020). Additionally, concerns regarding its efficacy (Mounsey et al., 2017) and safety in certain situations (e.g., young children, during pregnancy or breast feeding) have prompted research efforts to discover new alternatives to be used in the treatment of CS. The present study aimed to evaluate the local and systemic changes that may accompany CS in both treated and untreated experimental animals, with evaluation of fluralaner (FLR) as a new scabicidal agent.